A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
This study is for men with advanced prostate cancer that has spread to other areas of the body and is no longer responding to standard hormone therapy. Doctors call this metastatic castration-resistant prostate cancer. The trial compares an experimental drug called BNT324 with a standard chemotherapy called docetaxel, which is given alongside steroid tablets. A computer randomly puts participants into one of two groups to receive either the new medicine or the standard treatment. Both the patient and the medical team will know which treatment is being given. Doctors will follow each person's progress through regular scans, blood tests, and health checks. They want to find out which treatment keeps the cancer under control for longer, delays bone problems, relieves pain, and helps people live longer. Joining the study is completely voluntary.
At a glance
What is this study about?
Prostate cancer is one of the most common cancers in men. In some cases, the cancer spreads beyond the prostate to bones or other organs, and standard treatments that lower hormone levels stop working well. When this happens, doctors need other effective treatments to keep the cancer from growing.
Currently, a chemotherapy drug called docetaxel, given with a daily steroid tablet, is a common and proven treatment for advanced prostate cancer. This clinical trial is testing whether a new medicine called BNT324 works better than docetaxel at slowing the disease and helping patients live longer, fuller lives.
Because this is a Phase 3 trial, it is one of the final stages of research before a medicine can be approved for general use. The study is 'open-label', which means you and your care team will know exactly which treatment you are receiving. It is also randomised, meaning a computer assigns you to either BNT324 or standard chemotherapy by chance.
Finding new ways to treat advanced prostate cancer is crucial. If BNT324 proves effective, it could offer a valuable new option to help control tumour growth, ease bone pain, prevent fractures, and improve daily life for men facing this illness.
Key takeaways
- The trial compares a new drug, BNT324, with standard chemotherapy (docetaxel) for advanced prostate cancer.
- It is for adult men whose cancer has spread and is no longer held back by hormone therapy.
- A computer randomly chooses which of the two active treatments you receive.
- Researchers will monitor how well the treatments slow cancer growth, manage pain, and extend life.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
This trial is open to adult men aged 18 and older who have been diagnosed with advanced prostate cancer that has spread to other parts of the body. To take part, your cancer must be continuing to grow even though you have had treatments to block or lower testosterone.
You will need to be well enough in your day-to-day life to attend hospital appointments and cope with cancer therapy. Because this trial compares two active treatments, your general health, heart, kidneys, and liver must meet certain safety standards.
Your cancer specialist will review your previous treatments and test results to decide whether this trial is safe and appropriate for you. Men with certain other serious health issues or specific past cancer therapies may not be able to join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am a man aged 18 or older.
- I have been diagnosed with prostate cancer that has spread to other parts of my body.
- My cancer is growing or spreading despite standard hormone treatments.
- I am well enough to carry out daily activities and attend hospital visits.
- My doctor believes I am fit enough to receive chemotherapy or targeted cancer medicines.
What does participation involve?
Taking part involves regular visits to a hospital or specialist cancer clinic. If you are placed in the docetaxel group, you will receive the chemotherapy as a drip into a vein and take steroid tablets at home. If you are placed in the BNT324 group, you will receive the study medicine through a drip. You will have regular physical exams, blood tests (including checks on your PSA levels), and imaging scans such as CT or bone scans to see how your body is responding. You will also be asked to answer simple questions about your pain levels and daily activities. Treatment usually continues for as long as it helps keep the cancer in check without causing severe side effects, followed by regular check-ins with your care team.
Potential risks and benefits
Locations (6)
- —UnverifiedBelgium
- —UnverifiedSpain
- —UnverifiedItaly
- —UnverifiedPoland
- —UnverifiedGermany
- —UnverifiedHungary
Common questions
Will I receive a dummy treatment (placebo)?
No. Everyone in this study receives an active cancer treatment—either the experimental medicine BNT324 or the standard chemotherapy drug docetaxel.
Can I choose which treatment I get?
No. A computer programme assigns participants to either BNT324 or docetaxel by chance. This ensures the trial results are fair and unbiased.
Do I have to pay to take part in this trial?
No. The trial medication, extra tests, and study appointments are provided free of charge, and taking part will not affect your normal NHS care.
What happens if my cancer gets worse during the study?
Your doctor will check your scans and blood tests regularly. If the treatment is no longer working, you will stop it, and your doctor will discuss other treatment options with you.
Can I stop taking part if I change my mind?
Yes. You have the right to leave the trial at any point, for any reason, without giving an explanation. Your medical team will continue to care for you as normal.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.